

Intended for healthcare professionals

🗨️Rapid response to:

News

Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate

BMJ 2020; 371 doi: <https://doi.org/10.1136/bmj.m4347> (Published 09 November 2020) Cite this as: BMJ 2020;371:m4347

[Read our latest coverage of the coronavirus outbreak](#)

- [Article](#)
- [Related content](#)
- [Article metrics](#)
- [Rapid responses](#)
- [Response](#)

Rapid Response:

Re: Covid-19: Vaccine candidate may be more than 90% effective, interim results indicate

Dear Editor

The PR Press release by Pfizer concerning their Cov-19 vaccine being 90% effective is very misleading. They do not show any supporting evidence in the form of a peer reviewed publication in which the clinical trial data can be closely scrutinised.

My impression on reading their press release was that it was timed for the benefit of share holders and the stock market and the election of a new US President.

It is very doubtful that this vaccine will in fact be 90% effective on deployment. Its storage at -70C poses logistics problems, making it impractical for UK wide use, also it is a two shot vaccine. By the time it passes regulatory approval the Sars-cov-2 virus will have mutated again, reducing its efficacy still further.

It still has not gone through rigorous clinical safety trials and evaluation necessary to comply with UK and EU pharmaceutical legislation; remember, if used in UK it will still be under the control of European Medicine's Agency, whose office in London cannot close until 2039!

Competing interests: No competing interests

10 November 2020

Roger J Corder
Biomedical Scientist - Retired
Dublin 2 Ireland

